GlassScriptPhysician profile
Victor Gorloff
NPI 1194794396
$13,476.24
in general payments reported to CMS, 2019-2025
44 companies · $2,468 in 2025
The $2,468 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,824 · 2020: $1,442 · 2021: $1,425 · 2022: $1,979 · 2023: $2,220 · 2024: $2,118 · 2025: $2,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,490 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,490.22 |
| Education | $315.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,272.50 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,341.05 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $967.44 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $874.60 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Philips North America LLC | $852.82 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $759.92 | 2019-2025 | Dupixent |
| Insmed, INC. | $540.02 | 2020-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $342.37 | 2019-2022 | |
| Grifols USA, LLC | $327.73 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Sunovion Pharmaceuticals INC. | $300.51 | 2019-2021 | |
| Amgen INC. | $272.24 | 2019-2025 | Tezspire |
| Electromed, INC. | $242.09 | 2021-2025 | Smartvest |
| Mylan Specialty L.P. | $222.97 | 2019-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $216.97 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $166.37 | 2019-2024 | Opsumit, Uptravi |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $161.62 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $154.73 | 2020-2025 | Belsomra, Verquvo, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $116.84 | 2020-2024 | Glassia, Aralast |
| Vifor Pharma, INC. | $112.50 | 2024-2025 | Zemaira |
| Pfizer INC. | $104.24 | 2019-2025 | |
| Harmony Biosciences LLC | $99.88 | 2021-2022 | |
| United Therapeutics Corporation | $93.94 | 2021-2025 | Tyvaso, Tyvaso |
| Verona Pharma, INC. | $91.71 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $87.54 | 2019-2022 | |
| Advanced Respiratory, INC | $87.29 | 2021 | |
| Baxter Healthcare | $83.45 | 2023-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Novartis Pharmaceuticals Corporation | $83.07 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $77.13 | 2020-2023 | Acthar |
| Viatris Specialty LLC | $59.55 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $45.96 | 2023-2025 | Inspire |
| Abbvie INC. | $42.42 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $32.46 | 2023 | Ultomiris |
| Axsome Therapeutics, INC. | $31.78 | 2023 | Sunosi |
| Azurity Pharmaceuticals, INC. | $29.01 | 2024-2025 | Alvesco, Horizant |
| Gilead Sciences, INC. | $28.29 | 2022 | |
| Optinose US, INC. | $23.28 | 2025 | |
| Pulmonx Corporation | $21.53 | 2022 | |
| Lilly USA, LLC | $19.81 | 2025 | Zepbound |
| Alk-Abello, INC | $18.88 | 2025 | Ragwitek, Grastek, Odactra |
| Covis Pharma Gmbh | $15.21 | 2022 | |
| Amarin Pharma, INC. | $14.49 | 2021 | |
| Novo Nordisk INC | $13.60 | 2019 | |
| Angiodynamics, INC. | $13.26 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Gorloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.